Skip to content

Study · Animal study (in vivo) · rat · 2021

19 results

Anti-depressant effect of cerebrolysin in reserpine-induced depression in rats: Behavioral, biochemical, molecular and immunohistochemical evidence.

El-Marasy SA, El Awdan SA, Hassan A, Ahmed-Farid OA, Ogaly HA

Chemico-biological interactions3 Dec 2020Cited by 37 (Europe PMC)

PMID33279466 (opens in a new tab)DOI10.1016/j.cbi.2020.109329 (opens in a new tab)PepBankPUB-33279466
Publisher pagePubMedAsk about this study
Jump to 19 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study19

19 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In reserpine-treated rats, CBL reversed reduced latency to immobility in the forced swimming test.

    In plain wordsIn rats, CBL increased latency to immobility compared with reserpine treatment.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseLatency to immobility
    Study

    ratn: not reported in source

    Reserpine-induced depression
    Comparator
    Reserpine
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    2.5, 5 ml/kg · intraperitoneal · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    CBL reversed Reserpine-induced reduction in latency to immobility and prolongation of immobility time in the forced swimming test (FST)
    2 context sentences
    Summary · context
    Rats received either the vehicle or Reserpine (0.5 mg/kg, i.p.) for 14 days.
    Summary · context
    The other three groups were pretreated with CBL (2.5, 5 ml/kg; i.p.) or fluoxetine (FLU) (5 mg/kg, p.o.), respectively for 14 days, 30 min before reserpine injection.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In reserpine-treated rats, CBL reversed prolonged immobility time in the forced swimming test.

    In plain wordsIn rats, CBL reduced immobility time compared with reserpine treatment.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseImmobility time
    Study

    ratn: not reported in source

    Reserpine-induced depression
    Comparator
    Reserpine
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    2.5, 5 ml/kg · intraperitoneal · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    CBL reversed Reserpine-induced reduction in latency to immobility and prolongation of immobility time in the forced swimming test (FST)
    2 context sentences
    Summary · context
    Rats received either the vehicle or Reserpine (0.5 mg/kg, i.p.) for 14 days.
    Summary · context
    The other three groups were pretreated with CBL (2.5, 5 ml/kg; i.p.) or fluoxetine (FLU) (5 mg/kg, p.o.), respectively for 14 days, 30 min before reserpine injection.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In reserpine-treated rats, CBL reduced MDA.

    In plain wordsIn rats, CBL reduced MDA compared with reserpine treatment.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseMDA
    Study

    ratn: not reported in source

    Reserpine-induced depression
    Comparator
    Reserpine
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    2.5, 5 ml/kg · intraperitoneal · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    reduced malondialdehyde (MDA)
    2 context sentences
    Summary · context
    Rats received either the vehicle or Reserpine (0.5 mg/kg, i.p.) for 14 days.
    Summary · context
    The other three groups were pretreated with CBL (2.5, 5 ml/kg; i.p.) or fluoxetine (FLU) (5 mg/kg, p.o.), respectively for 14 days, 30 min before reserpine injection.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In reserpine-treated rats, CBL elevated GSH.

    In plain wordsIn rats, CBL increased GSH compared with reserpine treatment.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseGSH
    Study

    ratn: not reported in source

    Reserpine-induced depression
    Comparator
    Reserpine
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    2.5, 5 ml/kg · intraperitoneal · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    elevated reduced glutathione (GSH)
    2 context sentences
    Summary · context
    Rats received either the vehicle or Reserpine (0.5 mg/kg, i.p.) for 14 days.
    Summary · context
    The other three groups were pretreated with CBL (2.5, 5 ml/kg; i.p.) or fluoxetine (FLU) (5 mg/kg, p.o.), respectively for 14 days, 30 min before reserpine injection.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In reserpine-treated rats, CBL reduced TNF-alpha.

    In plain wordsIn rats, CBL reduced TNF-alpha compared with reserpine treatment.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseTNF-alpha
    Study

    ratn: not reported in source

    Reserpine-induced depression
    Comparator
    Reserpine
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    2.5, 5 ml/kg · intraperitoneal · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    reduced tumor necrosis factor-alpha (TNF-ɑ)
    2 context sentences
    Summary · context
    Rats received either the vehicle or Reserpine (0.5 mg/kg, i.p.) for 14 days.
    Summary · context
    The other three groups were pretreated with CBL (2.5, 5 ml/kg; i.p.) or fluoxetine (FLU) (5 mg/kg, p.o.), respectively for 14 days, 30 min before reserpine injection.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In reserpine-treated rats, CBL elevated cortical and hippocampal BDNF contents.

    In plain wordsIn rats, CBL increased brain BDNF contents compared with reserpine treatment.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseBDNF brain contents
    Study

    ratn: not reported in source

    Reserpine-induced depression
    Comparator
    Reserpine
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    2.5, 5 ml/kg · intraperitoneal · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    and elevated BDNF cortical and hippocampal brain contents.
    2 context sentences
    Summary · context
    Rats received either the vehicle or Reserpine (0.5 mg/kg, i.p.) for 14 days.
    Summary · context
    The other three groups were pretreated with CBL (2.5, 5 ml/kg; i.p.) or fluoxetine (FLU) (5 mg/kg, p.o.), respectively for 14 days, 30 min before reserpine injection.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In reserpine-treated rats, CBL elevated cortical and hippocampal PKA protein expression.

    In plain wordsIn rats, CBL increased brain PKA protein expression compared with reserpine treatment.

    Peptide
    Cerebrolysin
    Outcome
    IncreasePKA protein expression
    Study

    ratn: not reported in source

    Reserpine-induced depression
    Comparator
    Reserpine
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    2.5, 5 ml/kg · intraperitoneal · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    CBL elevated protein kinase A (PKA) and nuclear factor kappa-B (NF-κB) cortical and hippocampal protein expressions.
    2 context sentences
    Summary · context
    Rats received either the vehicle or Reserpine (0.5 mg/kg, i.p.) for 14 days.
    Summary · context
    The other three groups were pretreated with CBL (2.5, 5 ml/kg; i.p.) or fluoxetine (FLU) (5 mg/kg, p.o.), respectively for 14 days, 30 min before reserpine injection.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In reserpine-treated rats, CBL elevated cortical and hippocampal NF-κB protein expression.

    In plain wordsIn rats, CBL increased brain NF-κB protein expression compared with reserpine treatment.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseNF-kappaB protein expression
    Study

    ratn: not reported in source

    Reserpine-induced depression
    Comparator
    Reserpine
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    2.5, 5 ml/kg · intraperitoneal · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    CBL elevated protein kinase A (PKA) and nuclear factor kappa-B (NF-κB) cortical and hippocampal protein expressions.
    2 context sentences
    Summary · context
    Rats received either the vehicle or Reserpine (0.5 mg/kg, i.p.) for 14 days.
    Summary · context
    The other three groups were pretreated with CBL (2.5, 5 ml/kg; i.p.) or fluoxetine (FLU) (5 mg/kg, p.o.), respectively for 14 days, 30 min before reserpine injection.
  9. 09AnimalAnimal study (in vivo)Mechanism

    In reserpine-treated rats, CBL ameliorated alterations in cortical and hippocampal AKT mRNA expression.

    In plain wordsIn rats, CBL improved altered brain AKT gene expression compared with reserpine treatment.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedAKT mRNA expression
    Study

    ratn: not reported in source

    Reserpine-induced depression
    Comparator
    Reserpine
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    2.5, 5 ml/kg · intraperitoneal · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    CBL also ameliorated alterations in mRNA expressions of protein kinase B (AKT), CREB and BDNF in the cortical and hippocampal tissues.
    2 context sentences
    Summary · context
    Rats received either the vehicle or Reserpine (0.5 mg/kg, i.p.) for 14 days.
    Summary · context
    The other three groups were pretreated with CBL (2.5, 5 ml/kg; i.p.) or fluoxetine (FLU) (5 mg/kg, p.o.), respectively for 14 days, 30 min before reserpine injection.
  10. 10AnimalAnimal study (in vivo)Mechanism

    In reserpine-treated rats, CBL ameliorated alterations in cortical and hippocampal CREB mRNA expression.

    In plain wordsIn rats, CBL improved altered brain CREB gene expression compared with reserpine treatment.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedCREB mRNA expression
    Study

    ratn: not reported in source

    Reserpine-induced depression
    Comparator
    Reserpine
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    2.5, 5 ml/kg · intraperitoneal · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    CBL also ameliorated alterations in mRNA expressions of protein kinase B (AKT), CREB and BDNF in the cortical and hippocampal tissues.
    2 context sentences
    Summary · context
    Rats received either the vehicle or Reserpine (0.5 mg/kg, i.p.) for 14 days.
    Summary · context
    The other three groups were pretreated with CBL (2.5, 5 ml/kg; i.p.) or fluoxetine (FLU) (5 mg/kg, p.o.), respectively for 14 days, 30 min before reserpine injection.
  11. 11AnimalAnimal study (in vivo)Mechanism

    In reserpine-treated rats, CBL ameliorated alterations in cortical and hippocampal BDNF mRNA expression.

    In plain wordsIn rats, CBL improved altered brain BDNF gene expression compared with reserpine treatment.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedBDNF mRNA expression
    Study

    ratn: not reported in source

    Reserpine-induced depression
    Comparator
    Reserpine
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    2.5, 5 ml/kg · intraperitoneal · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    CBL also ameliorated alterations in mRNA expressions of protein kinase B (AKT), CREB and BDNF in the cortical and hippocampal tissues.
    2 context sentences
    Summary · context
    Rats received either the vehicle or Reserpine (0.5 mg/kg, i.p.) for 14 days.
    Summary · context
    The other three groups were pretreated with CBL (2.5, 5 ml/kg; i.p.) or fluoxetine (FLU) (5 mg/kg, p.o.), respectively for 14 days, 30 min before reserpine injection.
  12. 12AnimalAnimal study (in vivo)Mechanism

    In reserpine-treated rats, CBL elevated cortical and hippocampal nor-epinephrine contents.

    In plain wordsIn rats, CBL increased brain nor-epinephrine compared with reserpine treatment.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseNor-epinephrine contents
    Study

    ratn: not reported in source

    Reserpine-induced depression
    Comparator
    Reserpine
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    2.5, 5 ml/kg · intraperitoneal · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    CBL elevated nor-epinephrine (NE), serotonin (5-HT), and dopamine (DA) and reduced 5-Hydroxyindoleacetic acid (5-HTAA), 3,4-Dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) cortical and hippocampal contents.
    2 context sentences
    Summary · context
    Rats received either the vehicle or Reserpine (0.5 mg/kg, i.p.) for 14 days.
    Summary · context
    The other three groups were pretreated with CBL (2.5, 5 ml/kg; i.p.) or fluoxetine (FLU) (5 mg/kg, p.o.), respectively for 14 days, 30 min before reserpine injection.
  13. 13AnimalAnimal study (in vivo)Mechanism

    In reserpine-treated rats, CBL elevated cortical and hippocampal serotonin contents.

    In plain wordsIn rats, CBL increased brain serotonin compared with reserpine treatment.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseSerotonin contents
    Study

    ratn: not reported in source

    Reserpine-induced depression
    Comparator
    Reserpine
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    2.5, 5 ml/kg · intraperitoneal · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    CBL elevated nor-epinephrine (NE), serotonin (5-HT), and dopamine (DA) and reduced 5-Hydroxyindoleacetic acid (5-HTAA), 3,4-Dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) cortical and hippocampal contents.
    2 context sentences
    Summary · context
    Rats received either the vehicle or Reserpine (0.5 mg/kg, i.p.) for 14 days.
    Summary · context
    The other three groups were pretreated with CBL (2.5, 5 ml/kg; i.p.) or fluoxetine (FLU) (5 mg/kg, p.o.), respectively for 14 days, 30 min before reserpine injection.
  14. 14AnimalAnimal study (in vivo)Mechanism

    In reserpine-treated rats, CBL elevated cortical and hippocampal dopamine contents.

    In plain wordsIn rats, CBL increased brain dopamine compared with reserpine treatment.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseDopamine contents
    Study

    ratn: not reported in source

    Reserpine-induced depression
    Comparator
    Reserpine
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    2.5, 5 ml/kg · intraperitoneal · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    CBL elevated nor-epinephrine (NE), serotonin (5-HT), and dopamine (DA) and reduced 5-Hydroxyindoleacetic acid (5-HTAA), 3,4-Dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) cortical and hippocampal contents.
    2 context sentences
    Summary · context
    Rats received either the vehicle or Reserpine (0.5 mg/kg, i.p.) for 14 days.
    Summary · context
    The other three groups were pretreated with CBL (2.5, 5 ml/kg; i.p.) or fluoxetine (FLU) (5 mg/kg, p.o.), respectively for 14 days, 30 min before reserpine injection.
  15. 15AnimalAnimal study (in vivo)Mechanism

    In reserpine-treated rats, CBL reduced cortical and hippocampal 5-HTAA contents.

    In plain wordsIn rats, CBL reduced brain 5-HTAA compared with reserpine treatment.

    Peptide
    Cerebrolysin
    Outcome
    Decrease5-HTAA contents
    Study

    ratn: not reported in source

    Reserpine-induced depression
    Comparator
    Reserpine
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    2.5, 5 ml/kg · intraperitoneal · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    CBL elevated nor-epinephrine (NE), serotonin (5-HT), and dopamine (DA) and reduced 5-Hydroxyindoleacetic acid (5-HTAA), 3,4-Dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) cortical and hippocampal contents.
    2 context sentences
    Summary · context
    Rats received either the vehicle or Reserpine (0.5 mg/kg, i.p.) for 14 days.
    Summary · context
    The other three groups were pretreated with CBL (2.5, 5 ml/kg; i.p.) or fluoxetine (FLU) (5 mg/kg, p.o.), respectively for 14 days, 30 min before reserpine injection.
  16. 16AnimalAnimal study (in vivo)Mechanism

    In reserpine-treated rats, CBL reduced cortical and hippocampal DOPAC contents.

    In plain wordsIn rats, CBL reduced brain DOPAC compared with reserpine treatment.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseDOPAC contents
    Study

    ratn: not reported in source

    Reserpine-induced depression
    Comparator
    Reserpine
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    2.5, 5 ml/kg · intraperitoneal · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    CBL elevated nor-epinephrine (NE), serotonin (5-HT), and dopamine (DA) and reduced 5-Hydroxyindoleacetic acid (5-HTAA), 3,4-Dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) cortical and hippocampal contents.
    2 context sentences
    Summary · context
    Rats received either the vehicle or Reserpine (0.5 mg/kg, i.p.) for 14 days.
    Summary · context
    The other three groups were pretreated with CBL (2.5, 5 ml/kg; i.p.) or fluoxetine (FLU) (5 mg/kg, p.o.), respectively for 14 days, 30 min before reserpine injection.
  17. 17AnimalAnimal study (in vivo)Mechanism

    In reserpine-treated rats, CBL reduced cortical and hippocampal HVA contents.

    In plain wordsIn rats, CBL reduced brain HVA compared with reserpine treatment.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseHVA contents
    Study

    ratn: not reported in source

    Reserpine-induced depression
    Comparator
    Reserpine
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    2.5, 5 ml/kg · intraperitoneal · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    CBL elevated nor-epinephrine (NE), serotonin (5-HT), and dopamine (DA) and reduced 5-Hydroxyindoleacetic acid (5-HTAA), 3,4-Dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) cortical and hippocampal contents.
    2 context sentences
    Summary · context
    Rats received either the vehicle or Reserpine (0.5 mg/kg, i.p.) for 14 days.
    Summary · context
    The other three groups were pretreated with CBL (2.5, 5 ml/kg; i.p.) or fluoxetine (FLU) (5 mg/kg, p.o.), respectively for 14 days, 30 min before reserpine injection.
  18. 18AnimalAnimal study (in vivo)Efficacy outcome

    In reserpine-treated rats, Cerebrolysin effects paralleled those observed with fluoxetine.

    In plain wordsIn rats, Cerebrolysin effects paralleled those observed with fluoxetine.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedOverall antidepressant effects compared with fluoxetine
    Study

    ratn: not reported in source

    Reserpine-induced depression
    Comparator
    Fluoxetine
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    2.5, 5 ml/kg · intraperitoneal · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    CBL effects were in parallel to those observed with the standard anti-depressant drug, FLU.
    2 context sentences
    Summary · context
    Rats received either the vehicle or Reserpine (0.5 mg/kg, i.p.) for 14 days.
    Summary · context
    The other three groups were pretreated with CBL (2.5, 5 ml/kg; i.p.) or fluoxetine (FLU) (5 mg/kg, p.o.), respectively for 14 days, 30 min before reserpine injection.
  19. 19AnimalAnimal study (in vivo)Efficacy outcome

    In reserpine-treated rats, Cerebrolysin ameliorated histopathological changes.

    In plain wordsIn rats, Cerebrolysin improved tissue changes associated with reserpine-induced depression.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedHistopathological changes
    Study

    ratn: not reported in source

    Reserpine-induced depression
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    2.5, 5 ml/kg · intraperitoneal · 14 daysAs given in this study (rat).

    Source sentences

    Summary
    This study shows that CBL exerted anti-depressant effect evidenced by attenuation of oxidative stress and inflammation as well as enhancement of neurogenesis, amelioration of monoaminergic system and histopathological changes.
    2 context sentences
    Summary · context
    Rats received either the vehicle or Reserpine (0.5 mg/kg, i.p.) for 14 days.
    Summary · context
    The other three groups were pretreated with CBL (2.5, 5 ml/kg; i.p.) or fluoxetine (FLU) (5 mg/kg, p.o.), respectively for 14 days, 30 min before reserpine injection.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.